[Arsenic trioxide in the treatment of acute promyelocytic leukaemia].
Arsenic trioxide has drawn renewed interest in onco-haematological therapy. Based on a number of studies quoted in this paper, it has been approved by FDA and EMEA for remission induction and consolidation therapy of acute promyelocytic leukaemia in patients refractory to treatment using trans-retinoic acid and anthracyclines. In addition to briefly discuss available therapeutic resources against this disease, this review attempts to provide an in-depth view of this drugâs characteristics and efficacy, as shown in several studies.
Ercilla Liceaga
M
M
Servicio de Farmacia. Hospital Donostia. edificio Aránzazu. San Sebastián. Spain. afarmaci@chdo.osakidetza.net
Andueza Granados
K
K
Fernández González
I
I
Barcia Romero
M J
MJ
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D010087:Oxides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000077237:Arsenic Trioxide
El trióxido de arsénico en el tratamiento de la leucemia promielocítica aguda.